The stock of the medical imaging contrast agent specialist soared this Monday, April 27, 2026, showing an increase of over 7% in mid-afternoon. This spectacular rebound brings the weekly performance to more than 26%, after several months of significant decline. The stock is now trading well above its short-term moving averages, in a nearly stable Parisian market context.
Weekly Rally Propels Stock into Technical Overbought Zone
Guerbet's stock is trading around €12.44 during the session, up 7.06% from last Friday's close of €11.62. Over seven days, the stock has accumulated a gain of 26.29%, a movement all the more remarkable as the stock still shows a decline of 34.46% over the past year. From a technical analysis perspective, the price has significantly crossed the upper boundary of the Bollinger Bands, set at €10.90, which constitutes a classic signal of potential overbuying. The stock is also well above its 50-day moving average (€10.89), which it crossed upwards last week. The RSI, at 67, is approaching the overheating zone without yet reaching it, reflecting the intensity of the recent acceleration. This movement occurs in a sluggish Parisian market: the CAC 40 is barely up 0.01% in session, while the SBF 120 is up 0.03%.
Busy Financial Calendar Ahead for the Group
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
While the stock is recovering some of the lost ground — it is still down more than 10% over three months — upcoming deadlines could provide crucial insights. Guerbet's annual general meeting is scheduled for Friday, May 22, 2026, an event likely to provide details on the group's strategy and distribution policy. Investors are then awaiting the publication of the second quarter's revenue, scheduled for Thursday, July 23, followed by the first half of 2026 results on Tuesday, September 15. It should be noted that the current price remains significantly below the 200-day moving average, which is at €15.26, a gap that illustrates the magnitude of the correction suffered over the past year. The former resistance of €11.62, corresponding to the last closing price, could now act as a support in case of consolidation. The very low beta of the stock (0.16) also indicates a historically limited sensitivity to general market movements, making the current rebound all the more specific to the stock.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 573,8 millions d'euros
Quarterly revenue: 573,8 millions d'euros
Revenue growth: -2,2 %
Guidance from the release
Strongly negative free cash flow of between -€50 million and -€70 million, due to the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs
Risks mentioned
Ongoing contraction in sales in China due to policy to sharply reduce healthcare spending and gradual elimination of intermediaries
Planned slowdown in subcontracting activities at Gadopiclenol production site with Fill & Finish ending at end-2026
Continued normalisation at Raleigh industrial site with restructuring costs and redundancy plan in France
Opportunities identified
Strong momentum in Interventional Radiology business, up 6.6% with Lipiodol® driving growth in vascular embolization market
Recovery in activity in France and positive contribution from EMEA, Americas and Asia regions excluding China
Dynamic sales of Elucirem™ product offsetting some of the decline in other divisions
Outlook / guidance
Management commentary: For 2026, the Group's targets are: Revenue stable or showing a slight decrease at CER and on a like-for-like basis. Restated EBITDA margin rate of around 8%, including around €35 million related to the costs of the remediation plan at the Raleigh site. Strongly negative free cash flow of between -€50 million and -€70 million, due to the expected decrease in restated EBITDA, the increase in the CAPEX plan and non-recurring restructuring costs linked to the Group's transformation plan, including in particular the redundancy plan in France.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
